Status:
COMPLETED
Clinical Trial of Factor XIII (FXIII) Concentrate
Lead Sponsor:
Children's Hospital of Orange County
Collaborating Sponsors:
CSL Behring
Conditions:
Hemophilia
Factor XIII Deficiency
Eligibility:
All Genders
Phase:
NA
Brief Summary
Congenital deficiency of Factor XIII is a rare but potentially life threatening disorder. It is inherited in an autosomal recessive fashion. Infusion of Factor XIII has proved to be useful for prevent...
Eligibility Criteria
Inclusion
- Patients may be of either sex or age. Children and newborn infants are specifically included in this study.
- Patient must have documented congenital Factor XIII deficiency
- Patient or legal guardian must sign informed consent
- Patients who have negative serology for hepatitis B should receive Hepatitis B vaccination.
Exclusion
- Patient has acquired Factor XIII deficiency
Key Trial Info
Start Date :
January 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT00640289
Start Date
January 1 2000
End Date
December 1 2011
Last Update
November 7 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's Hospital of Orange Co.
Orange, California, United States, 92868